Fumarranol is a drug which acts as an inhibitor of the type 2 methionine aminopeptidase enzyme METAP2. It was derived by structural modification of the natural product fumagillin. It was originally developed as an anti-angiogenesis drug for the treatment of cancer,[1] but it was subsequently found to bind with high affinity to the METAP2 enzyme in malaria parasites and has been investigated as a potential treatment for malaria.[2][3]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C16H24O4 |
Molar mass | 280.364 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Lu J, Chong CR, Hu X, Liu JO (September 2006). "Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo". Journal of Medicinal Chemistry. 49 (19): 5645–8. doi:10.1021/jm060559v. PMID 16970390.
- ^ Chen X, Xie S, Bhat S, Kumar N, Shapiro TA, Liu JO (February 2009). "Fumagillin and fumarranol interact with P. falciparum methionine aminopeptidase 2 and inhibit malaria parasite growth in vitro and in vivo". Chemistry & Biology. 16 (2): 193–202. doi:10.1016/j.chembiol.2009.01.006. PMID 19246010.
- ^ Deu E (August 2017). "Proteases as antimalarial targets: strategies for genetic, chemical, and therapeutic validation". The FEBS Journal. 284 (16): 2604–2628. doi:10.1111/febs.14130. PMC 5575534. PMID 28599096.